Previous close | 3.6000 |
Open | 4.0900 |
Bid | 3.5000 |
Ask | 3.6000 |
Strike | 67.50 |
Expiry date | 2024-06-21 |
Day's range | 4.0900 - 4.0900 |
Contract range | N/A |
Volume | |
Open interest | 2.52k |
Gilead Sciences (GILD) reachead $64.70 at the closing of the latest trading day, reflecting a +1.33% change compared to its last close.
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
FOSTER CITY, Calif., June 06, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from the Phase 2b MYR204 open-label study assessing the efficacy and safety of the first-in-class entry inhibitor bulevirtide as monotherapy and in combination with pegylated interferon alfa-2a (PegIFN), in adults living with compensated chronic hepatitis delta virus (HDV) infection. Published in the New England Journal of Medicine (NEJM), the data demonstrate that the investigational combination of bul